Valuation : Edesa Biotech, Inc.

Market Cap 62.96M 54.15M 51.09M 46.54M 87.01M 6.02B 87.8M 608M 234M 3.05B 236M 231M 9.7B P/E 2026 *
-2.35x
P/E 2027 * -2.25x
Enterprise Value 62.96M 54.15M 51.09M 46.54M 87.01M 6.02B 87.8M 608M 234M 3.05B 236M 231M 9.7B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.5%
Yield 2026 *
-
Yield 2027 * -
1 day-1.27%
1 week-2.10%
Current month-1.58%
1 month-11.07%
3 months-10.56%
6 months-32.46%
Current year+228.17%
1 week 4.64
Extreme 4.6382
5.1
1 month 4.12
Extreme 4.12
6.67
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 31/07/2015
Director of Finance/CFO 57 30/04/2025
President 48 06/06/2019
Director TitleAgeSince
Chairman 50 06/06/2019
Director/Board Member 55 06/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Free

Founder

5,714 0.0593%
03/08/26 Free

Founder

5,324 0.0553%
02/07/26 Free

Founder

3,378 0.0380%
Change 5-day change 1-year change 3-year change Capi.($)
-1.27%-2.10%+90.73%-23.60% 62.96M
-0.25%-1.36%+44.08%+102.76% 68.24B
+1.03%-3.31%+31.95%+75.72% 62.23B
-1.18%+0.47%-12.78%+384.69% 27.8B
-1.05%-4.43%+30.56%+10.07% 24.86B
-1.76%-6.30%-4.55%-19.75% 24.22B
+0.24%-3.65%+14.52%-19.52% 19.36B
-1.86%-2.22%+202.03%+353.89% 17.28B
-1.94%-4.94%-5.29%+495.65% 14.46B
-1.54%-2.88%+52.33%+159.75% 14.23B
Average -0.96%-3.18%+44.36%+151.96% 27.27B
Weighted average by Cap. -0.50%-3.10%+35.70%+137.00%

Financials

2026 *2027 *
Net sales - -
Net income -17.52M -15.07M -14.22M -12.95M -24.22M -1.68B -24.44M -169M -65.18M -850M -65.81M -64.37M -2.7B -29.25M -25.16M -23.74M -21.62M -40.42M -2.8B -40.79M -283M -109M -1.42B -110M -107M -4.51B
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
-
Date Price Change Volume
10/09/26 US$4.660 -1.27% 40,237
09/09/26 US$4.720 -0.21% 32,143
08/09/26 US$4.730 0.00% 32,025
04/09/26 US$4.730 -0.63% 36,375
03/09/26 US$4.760 0.00% 26,231
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.660USD
Average target price
16.33USD
Spread / Average Target
+250.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!